Related Experiment Videos
Rotavirus virus-like particles administered mucosally induce protective immunity
C M O'Neal1, S E Crawford, M K Estes
1Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA.
Journal of Virology
|October 29, 1997
Summary
Intranasal rotavirus virus-like particle (VLP) vaccines, even without neutralization antigens, provided complete protection in mice. Cholera toxin enhanced VLP vaccine efficacy, allowing lower doses for significant protection against rotavirus infection.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Rotavirus is a leading cause of severe diarrheal disease in infants globally.
- Current rotavirus vaccines have limitations, necessitating the development of novel vaccine strategies.
- Mucosal vaccination offers a promising route for inducing targeted immunity against enteric pathogens like rotavirus.
Purpose of the Study:
- To evaluate the immunogenicity and protective efficacy of rotavirus virus-like particle (VLP) subunit vaccines administered via mucosal routes.
- To compare the effectiveness of oral versus intranasal administration of VLPs.
- To assess the role of cholera toxin as a mucosal adjuvant in enhancing VLP vaccine responses.
Main Methods:
- Production of rotavirus VLPs using baculovirus expression system.
- Administration of VLPs (2/6-VLPs and G3 2/6/7-VLPs) with or without cholera toxin via oral and intranasal routes in adult mice.
- Assessment of serum and intestinal antibody responses (IgA, IgG).
- Evaluation of protective efficacy through rotavirus challenge and measurement of virus shedding.
Main Results:
- Intranasal VLP administration induced superior serum and intestinal antibody responses compared to oral administration.
- All mice receiving intranasal VLPs were fully protected from rotavirus challenge, with no virus shedding.
- Oral VLP administration achieved partial protection (≥50% reduction in shedding) in 50% of mice at the highest dose.
- Cholera toxin significantly enhanced VLP immunogenicity and protective efficacy, enabling protection with 10-fold less immunogen.
- Protection was achieved with VLPs lacking neutralization antigens (VP7 and VP4).
Conclusions:
- Rotavirus VLPs administered mucosally, particularly intranasally, are highly immunogenic and protective.
- Intranasal mucosal vaccination with rotavirus VLPs offers a promising, safe, and non-replicating vaccine strategy.
- Cholera toxin serves as an effective adjuvant for rotavirus VLP vaccines, enhancing efficacy and reducing required dosage.